Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel, By Region

Description

List of Tables

The global dupixent market size is expected to reach USD 28.70 billion by 2034, according to a new study by Polaris Market Research. The report "Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Dupixent market refers to the global commercial landscape for dupilumab, a biologic medication that targets specific proteins involved in type 2 inflammation. This market includes all aspects from the research and development of dupilumab to its manufacturing, distribution, and sale, and ultimately its use by patients. Dupixent is a prescription-only medication primarily used to treat a range of chronic inflammatory conditions, including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and a specific type of chronic obstructive pulmonary disease. The market encompasses the entire value chain, involving pharmaceutical companies, healthcare providers, and the patients who benefit from this advanced therapy.

The Dupixent market has seen considerable growth and evolution, driven by the increasing understanding of type 2 inflammation and the significant unmet needs in treating associated chronic diseases. Initially approved for atopic dermatitis, Dupixent's market expansion has been greatly influenced by its subsequent regulatory approvals across various indications and age groups, making it a versatile treatment option. Its mechanism of action, which involves inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, differentiates it from traditional treatments and offers a targeted approach to managing these complex conditions. This has led to strong adoption among both prescribers and patients, contributing to its substantial presence in the global pharmaceutical landscape.

Dupixent Market Report Highlights

By indication, the atopic dermatitis (AD) segment held the largest share in 2024. Its widespread prevalence and Dupixent's established efficacy in treating moderate-to-severe forms of this chronic skin condition have ensured its leading position and continued demand within the market.

By distribution channel, the hospital pharmacies segment held the largest share in 2024 in Dupixent distribution. This is primarily because Dupixent, as a specialized biologic, often requires initial administration or close monitoring in a hospital setting, where healthcare professionals are equipped to manage its specific handling and patient education needs.

By region, North America is leading in the Dupixent market. This dominance is driven by its advanced healthcare infrastructure, high awareness and acceptance of innovative biologic therapies, favorable reimbursement policies, and a significant patient population suffering from type 2 inflammatory diseases. Asia Pacific is rapidly emerging as a dynamic and high-growth region for the market. This growth is propelled by several factors, including improving healthcare infrastructure, rising disposable incomes, and increasing awareness of advanced treatment options for chronic inflammatory diseases.

Key players in the market include Sanofi and Regeneron Pharmaceuticals.

Polaris Market Research has segmented the Dupixent market report based on indication, distribution channel, and region:

By Indication Outlook (Revenue - USD Billion, 2020-2034)

Atopic Dermatitis (AD)

Asthma

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Chronic Obstructive Pulmonary Disease (COPD)

Others

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Product Code: PM5988

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Dupixent Market Insights

4.1. Dupixent Market - Market Snapshot
4.2. Dupixent Market Dynamics
4.3. Pipeline Analysis
4.4. Market Concentration & Characteristics
- 4.4.1. Drivers and Opportunities
  - 4.4.1.1. Rising Prevalence of Type 2 Inflammatory Diseases
  - 4.4.1.2. Broadening of Approved Indications and Age Groups
- 4.4.2. Restraints and Challenges
  - 4.4.2.1. High treatment costs
4.5. Porter's Five Forces Analysis
- 4.5.1. Bargaining Power of Suppliers (Moderate)
- 4.5.2. Threats of New Entrants: (Low)
- 4.5.3. Bargaining Power of Buyers (Moderate)
- 4.5.4. Threat of Substitute (Moderate)
- 4.5.5. Rivalry among existing firms (High)
4.6. PESTEL Analysis
4.7. Dupixent Market Trends
4.8. Value Chain Analysis
4.9. COVID-19 Impact Analysis

5. Global Dupixent Market, by Indication

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Dupixent Market, by Indication, 2020-2034 (USD Billion)
5.3. Atopic Dermatitis (AD)
- 5.3.1. Global Dupixent Market, by Atopic Dermatitis (AD), by Region, 2020-2034 (USD Billion)
5.4. Asthma
- 5.4.1. Global Dupixent Market, by Asthma, by Region, 2020-2034 (USD Billion)
5.5. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- 5.5.1. Global Dupixent Market, by Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), by Region, 2020-2034 (USD Billion)
5.6. Chronic Obstructive Pulmonary Disease (COPD)
- 5.6.1. Global Dupixent Market, by Chronic Obstructive Pulmonary Disease (COPD), by Region, 2020-2034 (USD Billion)
5.7. Others
- 5.7.1. Global Dupixent Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Dupixent Market, by Distribution Channel

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
6.3. Hospital Pharmacies
- 6.3.1. Global Dupixent Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
6.4. Retail Pharmacies
- 6.4.1. Global Dupixent Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
6.5. Others
- 6.5.1. Global Dupixent Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Dupixent Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Dupixent Market Assessment, By Geography, 2020-2034 (USD Billion)
7.3. Dupixent Market - North America
- 7.3.1. North America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.3.2. North America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.3.3. Dupixent Market - U.S.
  - 7.3.3.1. U.S.: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.3.3.2. U.S.: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.3.4. Dupixent Market - Canada
  - 7.3.4.1. Canada: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.3.4.2. Canada: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
7.4. Dupixent Market - Europe
- 7.4.1. Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.4.2. Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.3. Dupixent Market - UK
  - 7.4.3.1. UK: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.3.2. UK: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.4. Dupixent Market - France
  - 7.4.4.1. France: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.4.2. France: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.5. Dupixent Market - Germany
  - 7.4.5.1. Germany: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.5.2. Germany: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.6. Dupixent Market - Italy
  - 7.4.6.1. Italy: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.6.2. Italy: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.7. Dupixent Market - Spain
  - 7.4.7.1. Spain: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.7.2. Spain: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.8. Dupixent Market - Netherlands
  - 7.4.8.1. Netherlands: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.8.2. Netherlands: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.9. Dupixent Market - Russia
  - 7.4.9.1. Russia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.9.2. Russia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.4.10. Dupixent Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.4.10.2. Rest of Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
7.5. Dupixent Market - Asia Pacific
- 7.5.1. Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.5.2. Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.3. Dupixent Market - China
  - 7.5.3.1. China: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.3.2. China: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.4. Dupixent Market - India
  - 7.5.4.1. India: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.4.2. India: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.5. Dupixent Market - Malaysia
  - 7.5.5.1. Malaysia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.5.2. Malaysia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.6. Dupixent Market - Japan
  - 7.5.6.1. Japan: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.6.2. Japan: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.7. Dupixent Market - Indonesia
  - 7.5.7.1. Indonesia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.7.2. Indonesia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.8. Dupixent Market - South Korea
  - 7.5.8.1. South Korea: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.8.2. South Korea: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.9. Dupixent Market - Australia
  - 7.5.9.1. Australia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.9.2. Australia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.5.10. Dupixent Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.5.10.2. Rest of Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
7.6. Dupixent Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.6.2. Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.3. Dupixent Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.6.3.2. Saudi Arabia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.4. Dupixent Market - UAE
  - 7.6.4.1. UAE: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.6.4.2. UAE: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.5. Dupixent Market - Israel
  - 7.6.5.1. Israel: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.6.5.2. Israel: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.6. Dupixent Market - South Africa
  - 7.6.6.1. South Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.6.6.2. South Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.6.7. Dupixent Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.6.7.2. Rest of Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
7.7. Dupixent Market - Latin America
- 7.7.1. Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
- 7.7.2. Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.3. Dupixent Market - Mexico
  - 7.7.3.1. Mexico: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.7.3.2. Mexico: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.4. Dupixent Market - Brazil
  - 7.7.4.1. Brazil: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.7.4.2. Brazil: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.5. Dupixent Market - Argentina
  - 7.7.5.1. Argentina: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.7.5.2. Argentina: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.7.6. Dupixent Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  - 7.7.6.2. Rest of Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Regeneron Pharmaceuticals
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Sanofi
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development